Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  MEDNAX Inc    MD

MEDNAX INC (MD)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Law Offices of Howard G. Smith Announces Investigation on Behalf of Mednax, Inc. Investors

share with twitter share with LinkedIn share with facebook
share via e-mail
0
07/14/2018 | 03:36am CEST

Law Offices of Howard G. Smith announces an investigation on behalf of Mednax, Inc. (“Mednax” or the “Company) (NYSE: MD) investors concerning the Company and its officers’ possible violations of federal securities laws.

On April 20, 2017, Mednax announced poor financial results for the first quarter of 2017, including missed earnings. Mednax also reported that “[s]ame-unit revenue from net reimbursement-related factors is expected to decline by 0.6 percent for the first quarter of 2017, compared to the first quarter of 2016, driven by a 90 basis point payor mix shift to government payors that impacted same-unit pricing negatively by 150 basis points.” On this news, Mednax’s share price fell $5.39, or 8.1%, to close at $61.30 per share on April 20, 2017.

Then, on July 28, 2017, during its second quarter earnings call, Mednax announced that the Company had failed to complete acquisitions of anesthesiologist practices during the quarter and that any future anesthesiologist acquisitions were unlikely, citing the “challenging” payor mix combined with “continued … growth in compensation expense for nurse anesthetists.” On this news, Mednax’s share price fell $8.76 or 15.5%, to close at $47.73 per share on July 28, 2017, thereby further injuring investors.

If you purchased Mednax securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to [email protected], or visit our website at www.howardsmithlaw.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.


© Business Wire 2018
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MEDNAX INC
07/20INVESTIGATION ALERT : The Schall Law Firm Announces it is Investigating Claims A..
BU
07/20MEDNAX INC : Notice: Pawar Law Group Announces Investigation of Securities Claim..
AC
07/20GLANCY PRONGAY & MURRAY LLP : Continues Investigation on Behalf of Mednax, Inc. ..
BU
07/20Rosen Law Firm Announces Investigation of Securities Claims Against Mednax, I..
BU
07/19MEDNAX : Radiology Solutions and vRad to Exhibit at AHRA 2018 Annual Meeting Jul..
BU
07/18MEDNAX : SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Notifies Investo..
PR
07/18Law Offices of Howard G. Smith Continues Investigation on Behalf of Mednax, I..
BU
07/17MEDNAX : RM LAW Announces Class Action Lawsuit Against MEDNAX, Inc.
PR
07/16GLANCY PRONGAY & MURRAY LLP : Announces Investigation on Behalf of Mednax, Inc. ..
BU
07/16MEDNAX INC : Pomerantz Law Firm Investigates Claims On Behalf of Investors of M..
AC
More news
News from SeekingAlpha
07/18Mednax, Envision Healthcare dip as Chanos talks short book 
07/17Ameri Holdings +40.7% after securing robotics project 
07/12Premarket analyst action - healthcare 
06/25Mednax -2% after court denies request for prelim injunction against Atrium He.. 
06/23STOCKS TO WATCH : More Trade Tiffs And Stress Tests 
Financials ($)
Sales 2018 3 708 M
EBIT 2018 508 M
Net income 2018 311 M
Debt 2018 1 726 M
Yield 2018 -
P/E ratio 2018 13,07
P/E ratio 2019 11,95
EV / Sales 2018 1,58x
EV / Sales 2019 1,58x
Capitalization 4 137 M
Chart MEDNAX INC
Duration : Period :
MEDNAX Inc Technical Analysis Chart | MD | US58502B1061 | 4-Traders
Technical analysis trends MEDNAX INC
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 15
Average target price 51,8 $
Spread / Average Target 19%
EPS Revisions
Managers
NameTitle
Roger J. Medel Chief Executive Officer & Director
Joseph M. Calabro President & Chief Operating Officer
Cesar L. Alvarez Chairman
Vivian Lopez-Blanco Chief Financial Officer & Treasurer
Robert C. Bryant Chief Information Officer & Senior Vice President
Sector and Competitors
1st jan.Capitalization (M$)
MEDNAX INC-18.69%4 137
HCA HOLDINGS (HOSPITAL CORPORATION AMERICA)22.95%37 620
FRESENIUS MEDICAL CARE-3.65%30 952
LABORATORY CORPORATION OF AMERICA HOLDINGS17.20%19 073
QUEST DIAGNOSTICS16.21%15 618
DAVITA-3.14%12 314